Efficacy and safety of low-dose colchicine after myocardial infarction

New England Journal of Medicine

Volumn 381, Issue 26, 2019, Pages 2497-2505

  Tardif, Jean Claude ^a   Kouz, Simon ^c   Waters, David D ^e   Bertrand, Olivier F ^d   Diaz, Rafael ^f   Maggioni, Aldo P ^g   Pinto, Fausto J ^h   Ibrahim, Reda ^a   Gamra, Habib ⁱ   Kiwan, Ghassan S ^j   Berry, Colin ^k   López Sendón, José ^l   Ostadal, Petr ^m   Koenig, Wolfgang ⁿ   Angoulvant, Denis ^o   Grégoire, Jean C ^a   Lavoie, Marc André ^a   Dubé, Marie Pierre ^a   Rhainds, David ^a   Provencher, Mylène ^b   Blondeau, Lucie ^b   Orfanos, Andreas ^b   L'Allier, Philippe L ^a   Guertin, Marie Claude ^b   Roubille, François ^p   more..

^a MONTREAL HEART INSTITUTE   (Canada)

^b Montreal Health Innovations Coordinating Centre   (Canada)

^c Centre Hospitalier Regional de Lanaudiere   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

^f Estudios Clínicos Latino América and Instituto Cardiovascular de Rosario   (Argentina)

^g ANMCO RESEARCH CENTER   (Italy)

^h HOSPITAL DE SANTA MARIA   (Portugal)

ⁱ FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^j Bellevue Medical Center   (Lebanon)

^k UNIVERSITY OF GLASGOW   (United Kingdom)

^l HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^m NA HOMOLCE HOSPITAL   (Czech Republic)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o UNIVERSITY HOSPITAL OF TOURS   (France)

^p UNIVERSITY OF MONTPELLIER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COLCHICINE; PLACEBO; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER;

ADULT; ANEMIA; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAZARD RATIO; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HUMAN CELL; INFECTION; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PERCUTANEOUS CORONARY INTERVENTION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; SEPTIC SHOCK; THROMBOCYTOPENIA; TREATMENT OUTCOME; AGED; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; INCIDENCE; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; MORTALITY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE;

AGED; ANGINA PECTORIS; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COLCHICINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; RECURRENCE; STROKE;

EID: 85075950640     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1912388     Document Type: Article

References (20)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
2. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31.
3. Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752-62.
4. Ravelli RB, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathminlike domain. Nature 2004; 428: 198-202.
5. Perico N, Ostermann D, Bontempeill M, et al. Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. J Am Soc Nephrol 1996;7:594-601.
6. Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 2007;56:3183-8.
7. Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy 2005;4:117-24.
8. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005;112:2012-6.
9. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61: 404-10.
10. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
11. Rogers JK, Pocock SJ, McMurray JJ, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail 2014; 16: 33-40.
12. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982; 10: 1100-20.
13. Lin DY, Wei LJ. The robust inference for the proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
14. Lin DY, Wei LJ, Yang I, Ying Z. Semi-parametric regression for the mean and rate functions of recurrent events. J R Stat Soc 2000;62:711-30.
15. Wei LJ, Glidden DV. An overview of statistical methods for multiple failure time data in clinical trials. Stat Med 1997; 16:833-9.
16. Ghosh D. Methods for analysis of multiple events in the presence of death. Control Clin Trials 2000; 21: 115-26.
17. Li QH, Lagakos SW. Use of the WeiLin-Weissfeld method for the analysis of a recurring and a terminating event. Stat Med 1997;16:925-40.
18. Metcalfe C, Thompson SG. The importance of varying the event generation process in simulation studies of statistical methods for recurrent events. Stat Med 2006;25:165-79.
19. Jahn-Eimermacher A. Comparison of the Andersen-Gill model with Poisson and negative binomial regression on recurrent event data. Comput Stat Data Anal 2008;52:4989-97.
20. Kocak Z, Akay H, Gucenmez S, Tufan A, Donderici O. Colchicine intoxication and infection risk: a case report. J Clin Pharm Ther 2008;33:451-2.